Researchers study improved delivery methods for antibiotics in respiratory infections
They detailed their findings at the European Respiratory Society conference on Friday.
The test was based on Staphylococcus aureus, a major bacterium responsible for hospital contracted infections, and it also plays a role with individuals with cystic fibrosis, a genetic disorder. In the test, the antibiotic clarithromycin in particle form, also known as CLARI-NPS, was able to reach points of infection at the individual cell level and biofilms.
"Neither of these locations is conducive to effective drug delivery through traditional routes," said Dr. Cristiane Carvalho-Wodarz of the Helmhotlz Institute for Pharmaceutical Research. "We were pleased to see that not only did the use of CLARI-NPs allow the uptake of the antibiotic by the lung cells, but also that there were no toxic effects on all the cell types on which we tested."
This method was tested on human bronchial cells in vitro. The next phase would be to utilize an animal model, and they plan to expand the drugs used in the nanoparticle process and delivery to determine efficacy of additional treatment options.
"Using nanoparticles to deliver drugs to a local site of infection is a promising strategy for overcoming side effects, increasing treatment efficacy, and overcoming resistance," Carvalho-Wodarz said.